Coeptis Therapeutics Holdings, Inc. (COEP)
COEP moved a median of -1.83% 30 minutes after news, and 0.00% by the close. How COEP actually reacts to news — the realized, point-in-time move the market made, measured across 81 labeled events over the last three years with zero look-ahead.
COEP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.26% | 27% | 44 |
| 30-min | -1.83% | 22% | 68 |
| 60-min | -2.00% | 26% | 69 |
| to close | 0.00% | 49% | 70 |
| Middle 50% of COEP reactions | -4.63% to 0.00% |
|---|---|
| Median reaction (30-min) | -1.83% |
| Measured reactions | 81 |
Half of all Coeptis Therapeutics Holdings, Inc. news events land between -4.63% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when COEP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to COEP's baseline. Nothing else.
Recent COEP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market | Press release | PR Newswire | — | — | |
| Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application | Press release | GlobeNewswire | — | -2.11% | |
| Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build | Press release | ACCESS Newswire | +0.45% | -4.93% | |
| Coeptis Receives Shareholder Approval Towards Z Squared Merger | Press release | GlobeNewswire | +0.00% | +2.18% | |
| Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared | Press release | GlobeNewswire | +0.00% | +1.13% | |
| Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage | Press release | ACCESS Newswire | -0.35% | -3.75% | |
| Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating | Press release | GlobeNewswire | +6.11% | +14.72% | |
| Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd | Press release | GlobeNewswire | -1.85% | +0.93% | |
| Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared | Press release | GlobeNewswire | -2.22% | -0.99% | |
| Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology | Press release | GlobeNewswire | — | -0.98% | |
| COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.00% | -9.41% | |
| Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement | Press release | GlobeNewswire | -4.91% | -30.00% | |
| COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology | Press release | GlobeNewswire | +0.01% | +7.53% | |
| Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline | Press release | GlobeNewswire | +1.46% | +0.36% | |
| COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan | Press release | GlobeNewswire | — | +2.16% | |
| COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing | Press release | GlobeNewswire | -0.54% | -14.96% | |
| COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network | Press release | GlobeNewswire | -0.54% | -14.96% | |
| COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing | Press release | GlobeNewswire | -0.54% | -14.96% | |
| COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups | Press release | GlobeNewswire | +1.02% | -1.32% | |
| COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration | Press release | PR Newswire | -1.60% | +7.80% | |
| Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation | Press release | PR Newswire | +2.28% | +8.28% | |
| Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation | Press release | PR Newswire | +2.39% | -15.30% | |
| Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) | Press release | PR Newswire | — | +10.20% | |
| Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform | Press release | PR Newswire | -1.72% | -3.16% | |
| Coeptis Therapeutics Announces Reverse Stock Split | Press release | PR Newswire | +3.35% | +17.47% | |
| Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies | Press release | PR Newswire | -15.47% | -29.67% | |
| Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies | Press release | PR Newswire | -8.50% | -7.00% | |
| Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries | Press release | PR Newswire | -1.80% | +19.28% | |
| Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development | Press release | PR Newswire | -5.54% | -5.91% | |
| Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use | Press release | PR Newswire | -3.44% | -8.26% | |
| Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy | Press release | PR Newswire | +0.93% | -1.95% | |
| Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing | Press release | PR Newswire | -0.33% | +1.87% | |
| Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders | Press release | PR Newswire | +0.00% | -5.13% | |
| Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering | Press release | PR Newswire | +0.00% | -6.63% | |
| Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting | Press release | PR Newswire | -0.51% | +2.26% | |
| Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 | Press release | PR Newswire | -0.67% | +1.20% | |
| Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting | Press release | PR Newswire | +0.00% | +8.71% | |
| Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award | Press release | PR Newswire | -2.73% | -4.64% | |
| Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK | Press release | PR Newswire | -2.17% | +0.00% | |
| Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections | Press release | PR Newswire | — | +1.68% | |
| Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 | Press release | PR Newswire | — | -9.54% | |
| Coeptis Therapeutics to Present at the Emerging Growth Conference | Press release | PR Newswire | -0.20% | +1.70% | |
| Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 | Press release | PR Newswire | -2.65% | -8.71% | |
| Coeptis Therapeutics Announces $2 Million Private Placement | Press release | PR Newswire | -0.43% | -0.76% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the COEP section they belong to.
Where else COEP is measured.
COEP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Coeptis Therapeutics Holdings, Inc.'s median reaction calculated?
Every labeled COEP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 81 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 22% of COEP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does COEP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.